Non-contrast imaging characteristics of papillary renal cell carcinoma: implications for diagnosis and subtyping

被引:0
|
作者
Badri, Anand V. [1 ]
Waingankar, Nikhil [2 ]
Edwards, Kristin [3 ]
Kutikov, Alexander [1 ]
Parsons, Rosaleen B. [3 ]
Chen, David Y. [1 ]
Smaldone, Marc C. [1 ]
Viterbo, Rosalia [1 ]
Greenberg, Richard E. [1 ]
Uzzo, Robert G. [1 ]
机构
[1] Fox Chase Canc Ctr, Div Urol Oncol, 3401 N Broad St, Philadelphia, PA 19140 USA
[2] Mt Sinai Hosp, Icahn Sch Med, Dept Populat Hlth Sci & Policy, Dept Urol, New York, NY 10029 USA
[3] Fox Chase Canc Ctr, Dept Radiol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
关键词
papillary; RCC; noncontrast; unenhanced; CT; radiomics; INCIDENTAL FINDINGS; WHITE PAPER; ANGIOMYOLIPOMA; CT; CLASSIFICATION; PREVALENCE; MANAGEMENT; FEATURES; UPDATE;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Current radiographic guidelines suggest unenhanced renal lesions < 20 Hounsfield Units (HU) are overwhelmingly benign, requiring no further evaluation. We evaluate our experience with papillary renal cell carcinoma (pRCC) presenting with low pre-contrast attenuation and the relationship of attenuation with histologic pRCC subtype. Materials and methods: We reviewed our institutional kidney cancer database for patients with pT1 or pT2 pRCC between 2003-2017. Tumors were categorized by papillary subtype by expert uropathologists. Preoperative CT images were analyzed at six regional tumor locations. Low, presumably benign, unenhanced median attenuation was defined as <= 20 HU. We calculated the frequency of pRCC with low attenuation and assessed the relationship between attenuation and pRCC subtype using logistic regression. Results: Sixty-one patients with evaluable imaging were included. Median tumor size was 6 cm (1.7 cm-15.3 cm) with 39% (n = 24) type-1 and 61% (n = 37) type-2. Half of all pRCC tumors (n = 30) exhibited very low pre-contrast attenuation ( < 20 HU), risking misdiagnosis as benign using current guidelines. Of these, 80% (n = 24) were type-2 with significant biological potential. Overall, type2 tumors demonstrated a lower pre-contrast attenuation than type-1 (median HU: 19.8 (1.5-42.3) versus 29.6 HU (10-45.8), p < 0.01; max HU: 25.3 versus 36.5 HU, p < 0.01). After adjustment, lower pre-contrast HU was an independent predictor of pRCC subtype associated with a 5.5-fold increase of being type-2 (OR = 5.47, p < 0.01). Conclusion: pRCCs may exhibit very low attenuation on pre-contrast CT. This appears more common among the more aggressive type-2 subtype. These data suggest that low attenuation ( < 20 HU) alone on non-contrast CT imaging is insufficient as a single parameter to rule out malignancy.
引用
收藏
页码:9916 / 9921
页数:6
相关论文
共 50 条
  • [21] Can virtual non-contrast imaging replace true non-contrast imaging in multiphase scanning of the neck region?
    Al-Difaie, Zaid
    Scheepers, Max H. M. C.
    Bouvy, Nicole D.
    Engelen, Sanne
    Havekes, Bas
    Postma, Alida A.
    ACTA RADIOLOGICA OPEN, 2023, 12 (09)
  • [22] THE CYTOLOGIC DIAGNOSIS OF PAPILLARY RENAL-CELL CARCINOMA
    COOKINGHAM, CL
    FLINT, A
    ACTA CYTOLOGICA, 1983, 27 (05) : 569 - 569
  • [23] THE PAPILLARY RENAL-CELL CARCINOMA - A DIFFICULT DIAGNOSIS
    SCHNEIDER, S
    BRAMBS, HJ
    RADIOLOGE, 1990, 30 (02): : 84 - 86
  • [24] MYOCARDIAL FIBROSIS IMAGING WITH MRI: CONTRAST OR NON-CONTRAST?
    Zheng, J.
    CARDIOLOGY, 2015, 132 : 77 - 77
  • [25] Re: The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management
    Laguna, M. Pilar
    JOURNAL OF UROLOGY, 2021, 206 (04): : 1060 - 1061
  • [26] Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy
    Lisha Wang
    Sean R Williamson
    Mingsheng Wang
    Darrell D Davidson
    Shaobo Zhang
    Lee Ann Baldridge
    Xiang Du
    Liang Cheng
    Molecular Cancer, 13
  • [27] Parametric imaging of clear cell and papillary renal cell carcinoma using contrast-enhanced ultrasound (CEUS)
    Ruebenthaler, J.
    Reimann, R.
    Hristova, P.
    Staehler, M.
    Reiser, M.
    Clevert, D. A.
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2016, 63 (02) : 89 - 97
  • [28] Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy
    Wang, Lisha
    Williamson, Sean R.
    Wang, Mingsheng
    Davidson, Darrell D.
    Zhang, Shaobo
    Baldridge, Lee Ann
    Du, Xiang
    Cheng, Liang
    MOLECULAR CANCER, 2014, 13
  • [29] Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC)
    Rysz, Jacek
    Franczyk, Beata
    Lawinski, Janusz
    Gluba-Brzozka, Anna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (01)
  • [30] CLINICAL CHARACTERISTICS OF ONCOCYTIC PAPILLARY RENAL CELL CARCINOMA
    Urge, Tomas
    Milan, Hora
    Hes, Ondrej
    Ferda, Jiri
    Chudacek, Zdenek
    Eret, Viktor
    Klecka, Jiri
    Michal, Michal
    Stransky, Petr
    JOURNAL OF UROLOGY, 2010, 183 (04): : E248 - E249